Analysts Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) PT at $20.38

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has received a consensus recommendation of “Buy” from the ten analysts that are presently covering the stock, Marketbeat reports. Eight analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $20.1111.

A number of equities research analysts have issued reports on the stock. HC Wainwright assumed coverage on shares of Trevi Therapeutics in a research report on Wednesday, May 28th. They issued a “buy” rating and a $21.00 target price for the company. Raymond James Financial cut their target price on shares of Trevi Therapeutics from $29.00 to $27.00 and set a “strong-buy” rating for the company in a research report on Friday, August 8th. Wall Street Zen downgraded shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, June 6th. Oppenheimer reiterated an “outperform” rating on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Finally, Cantor Fitzgerald assumed coverage on shares of Trevi Therapeutics in a research report on Tuesday, July 1st. They issued an “overweight” rating and a $25.00 target price for the company.

Trevi Therapeutics Stock Up 0.9%

TRVI stock opened at $7.49 on Friday. Trevi Therapeutics has a 12-month low of $2.36 and a 12-month high of $8.11. The company has a market cap of $912.13 million, a price-to-earnings ratio of -17.83 and a beta of 0.58. The company has a 50 day moving average of $6.76 and a two-hundred day moving average of $6.13.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. On average, research analysts anticipate that Trevi Therapeutics will post -0.49 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of TRVI. JPMorgan Chase & Co. raised its holdings in shares of Trevi Therapeutics by 120.5% during the 4th quarter. JPMorgan Chase & Co. now owns 221,664 shares of the company’s stock valued at $913,000 after purchasing an additional 121,147 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Trevi Therapeutics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 1,299,322 shares of the company’s stock valued at $5,354,000 after purchasing an additional 35,156 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Trevi Therapeutics by 40.7% during the 4th quarter. Wells Fargo & Company MN now owns 33,050 shares of the company’s stock valued at $136,000 after purchasing an additional 9,562 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Trevi Therapeutics by 21.2% during the 4th quarter. Invesco Ltd. now owns 23,621 shares of the company’s stock valued at $97,000 after purchasing an additional 4,133 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Trevi Therapeutics by 42.0% during the 4th quarter. Renaissance Technologies LLC now owns 100,400 shares of the company’s stock valued at $414,000 after purchasing an additional 29,700 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.